Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab versus Rebif in treatment-naive relapsing-remitting multiple sclerosis
ACTRN12608000435381Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- Sep 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial of alemtuzumab in multiple sclerosis (MS) (2 arms), sponsored by Sanofi. Primary endpoints: Time to sustained accumulation of disability and Relapse rate. Started Sep 2007; status: active, not recruiting.
02
Drugs
alemtuzumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on ACTRN12608000435381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12608000435381.